Oncology Central

Can we predict and prevent specific sites of metastases in breast cancer patients?


Despite improvements in breast cancer therapies, cancer cells frequently spread to distant organs years or decades after primary tumor surgery and adjuvant treatment. This expansion, known as metastasis, can bring about fatal consequences. Traditionally, the risk of metastasis has been predicted by prognostic factors such as tumor size, axillary lymph node status and histological grade. More recently, genomic tests have also been used for this purpose. The presence of ER, PR and ERBB2 gene amplification are currently key markers in the characterization of breast tumor type that drive the selection of specific therapies [1].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.